Sophie Liabeuf

7.0k total citations · 1 hit paper
143 papers, 4.6k citations indexed

About

Sophie Liabeuf is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sophie Liabeuf has authored 143 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Nephrology, 23 papers in Cardiology and Cardiovascular Medicine and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sophie Liabeuf's work include Dialysis and Renal Disease Management (49 papers), Parathyroid Disorders and Treatments (40 papers) and Chronic Kidney Disease and Diabetes (18 papers). Sophie Liabeuf is often cited by papers focused on Dialysis and Renal Disease Management (49 papers), Parathyroid Disorders and Treatments (40 papers) and Chronic Kidney Disease and Diabetes (18 papers). Sophie Liabeuf collaborates with scholars based in France, Belgium and United States. Sophie Liabeuf's co-authors include Ziad A. Massy, Gabriel Choukroun, Daniela Veit Barreto, Fellype Carvalho Barreto, Raymond Vanholder, Griet Glorieux, M. Temmar, Natalie Meert, Horst‐Dieter Lemke and Aurélie Lenglet and has published in prestigious journals such as PLoS ONE, The Journal of Clinical Endocrinology & Metabolism and International Journal of Molecular Sciences.

In The Last Decade

Sophie Liabeuf

135 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients

2009 750 citations Sophie Liabeuf, Griet Glorieux et al. Clinical Journal of the American Society of Nephrology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sophie Liabeuf France	33	2.6k	827	631	617	559	143	4.6k
Kook‐Hwan Oh South Korea	33	2.6k 1.0×	608 0.7×	900 1.4×	359 0.6×	617 1.1×	331	5.0k
Domenico Santoro Italy	39	2.0k 0.8×	691 0.8×	613 1.0×	410 0.7×	539 1.0×	277	5.2k
Martin H. de Borst Netherlands	39	2.1k 0.8×	833 1.0×	602 1.0×	1.1k 1.8×	506 0.9×	260	4.8k
Ho Jun Chin South Korea	36	1.9k 0.7×	581 0.7×	409 0.6×	368 0.6×	643 1.2×	188	4.0k
Barış Afşar Türkiye	35	1.9k 0.7×	746 0.9×	778 1.2×	307 0.5×	904 1.6×	218	4.5k
Yoshiharu Tsubakihara Japan	40	3.1k 1.2×	357 0.4×	832 1.3×	521 0.8×	588 1.1×	143	4.9k
Alejandro Martín‐Malo Spain	39	3.3k 1.3×	610 0.7×	1.1k 1.8×	478 0.8×	459 0.8×	158	5.4k
Cassianne Robinson‐Cohen United States	38	1.7k 0.7×	486 0.6×	672 1.1×	422 0.7×	666 1.2×	105	4.3k
Michele Andreucci Italy	42	2.4k 0.9×	987 1.2×	922 1.5×	280 0.5×	1.1k 1.9×	228	5.7k
Davide Bolignano Italy	38	2.8k 1.1×	970 1.2×	860 1.4×	324 0.5×	1.0k 1.9×	187	5.9k

Countries citing papers authored by Sophie Liabeuf

Since Specialization

Citations

This map shows the geographic impact of Sophie Liabeuf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sophie Liabeuf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sophie Liabeuf more than expected).

Fields of papers citing papers by Sophie Liabeuf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sophie Liabeuf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sophie Liabeuf. The network helps show where Sophie Liabeuf may publish in the future.

Co-authorship network of co-authors of Sophie Liabeuf

This figure shows the co-authorship network connecting the top 25 collaborators of Sophie Liabeuf. A scholar is included among the top collaborators of Sophie Liabeuf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sophie Liabeuf. Sophie Liabeuf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhu, Nanbo, Maria Eriksdotter, Sophie Liabeuf, et al.. (2025). Anticholinergic burden and incident dementia: a Swedish nationwide case-control study. Alzheimer s Research & Therapy. 17(1). 227–227.

Jaisson, Stéphane, Saïd Kamel, Gabriel Choukroun, et al.. (2025). Exploring the Interactions between Drugs and Metabolic Disturbances in CKD. Kidney360. 6(12). 2145–2156. 1 indexed citations

Laville, Solène M., Stéphane Jaisson, Philippe Gillery, et al.. (2025). Homocitrulline Is Associated with Cardiovascular Outcomes in Nondialysis Patients with CKD. Kidney360. 6(8). 1328–1337.

Liabeuf, Sophie, et al.. (2025). Drug Exposure in Chronic Kidney Disease: It Is Not Just About the Glomerular Filtration Rate. Fundamental and Clinical Pharmacology. 39(4). 1–10.

Laville, Solène M., Sophie Liabeuf, Benjamin Batteux, et al.. (2024). Medication-overuse headache: A pharmacovigilance study in France. Therapies. 79(5). 565–575. 1 indexed citations

Florens, Nans, Luc Frimat, Maurice Laville, et al.. (2024). Acute kidney injury as a key predictor of cardiovascular events in chronic kidney disease patients: the CKD-REIN study. Clinical Kidney Journal. 17(12). sfae337–sfae337. 4 indexed citations

Massy, Ziad A., Christian Jacquelinet, Natália Alencar de Pinho, et al.. (2024). The anticholinergic burden in patients with chronic kidney disease: Patterns, risk factors, and the link with cognitive impairment. Journal of the American Geriatrics Society. 73(2). 533–544. 1 indexed citations

Bonnet, Fabrice, Beverley Balkau, Oriane Lambert, et al.. (2024). The number of nephroprotection targets attained is associated with cardiorenal outcomes and mortality in patients with diabetic kidney disease. The CKD‐REIN cohort study. Diabetes Obesity and Metabolism. 26(5). 1908–1918. 3 indexed citations

Boucquemont, Julie, Oriane Lambert, Sophie Liabeuf, et al.. (2024). Urea Level and Depression in Patients with Chronic Kidney Disease. Toxins. 16(7). 326–326. 4 indexed citations

10.

Kamel, Saı̈d, Natália Alencar de Pinho, Nicolas Mansencal, et al.. (2024). Ionized and total magnesium levels in patients with chronic kidney disease: associated factors and outcomes. Clinical Kidney Journal. 17(4). sfae046–sfae046. 2 indexed citations

11.

Choukroun, Gabriel, et al.. (2023). Quantitative determination of plasma free and total concentrations of antivitamin K drugs using a new sensitive and rapid LC-MS/MS method: Application in hemodialysis patients. Clinica Chimica Acta. 548. 117498–117498.

12.

Liabeuf, Sophie, Youssef Bennis, Solène M. Laville, et al.. (2023). Statin therapy and the incidence of atherosclerotic cardiovascular events after kidney transplantation. Nephrology Dialysis Transplantation. 39(5). 818–829. 1 indexed citations

13.

Larabi, Islam Amine, Solène M. Laville, Christian Jacquelinet, et al.. (2023). Proton-Pump Inhibitors and Serum Concentrations of Uremic Toxins in Patients with Chronic Kidney Disease. Toxins. 15(4). 276–276. 4 indexed citations

14.

Liabeuf, Sophie, et al.. (2022). Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?. Toxins. 14(4). 280–280. 36 indexed citations

15.

Gras, Valérie, et al.. (2022). Use of the Capture-Recapture Method to Estimate the Frequency of Community- and Hospital-Acquired Drug-Induced Acute Kidney Injuries in French Databases. Frontiers in Pharmacology. 13. 899164–899164. 4 indexed citations

16.

Legrand, Karine, Karen Leffondré, Abdou Y. Omorou, et al.. (2022). Five-Year Symptom Trajectories in Nondialysis-Dependent CKD Patients. Clinical Journal of the American Society of Nephrology. 17(11). 1588–1597. 8 indexed citations

17.

Delaunay, Pascal, et al.. (2021). Impact of the COVID-19 outbreak on the reporting of adverse drug reactions associated with self-medication. Annales Pharmaceutiques Françaises. 79(5). 522–529. 21 indexed citations

18.

Pinho, Natália Alencar de, Élodie Speyer, Christian Combe, et al.. (2021). Réalité de la prise en charge de la maladie rénale chronique en néphrologie en France : étude de cohorte CKD-REIN. Néphrologie & Thérapeutique. 17(7). 496–506.

19.

Liabeuf, Sophie, Solène M. Laville, Griet Glorieux, et al.. (2020). Difference in Profiles of the Gut-Derived Tryptophan Metabolite Indole Acetic Acid between Transplanted and Non-Transplanted Patients with Chronic Kidney Disease. International Journal of Molecular Sciences. 21(6). 2031–2031. 16 indexed citations

20.

Vanmassenhove, Jill, Wim Van Biesen, Ziad A. Massy, et al.. (2019). Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury. International Urology and Nephrology. 51(2). 293–302. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact